Top entities: Aldeyra Therapeutics, Pomerantz LLP, United States — Food and Drug Administration, Reproxalap.

What category does this event fall under?

Regulatory — classified as class action lawsuit.

What is the market impact?

Direct. The market is significantly impacted by the 70.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 30, 2026. Coverage continues to evolve.

Regulatory class action lawsuit

Aldeyra Therapeutics faces class action

Q: When did this event occur?

First reported May 23, 2026; last updated May 30, 2026.

Analysis based on 6 articles · First reported May 23, 2026 · Last updated May 30, 2026

Sentiment

-70

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is significantly impacted by the 70.69% stock price drop of Aldeyra Therapeutics, reflecting investor loss of confidence due to the United States — Food and Drug Administration's rejection of its key drug candidate. This event also highlights the risks associated with pharmaceutical development and regulatory approvals, potentially affecting investor sentiment towards other biotech companies.

Pharmaceuticals Legal Services

Event Summary

A class action lawsuit has been filed against Aldeyra Therapeutics by Pomerantz LLP following a significant drop in the company's stock price. This decline occurred after the United States — Food and Drug Administration issued a Complete Response Letter for Aldeyra Therapeutics' investigational drug candidate, Reproxalap, for dry eye disease. The United States — Food and Drug Administration cited a 'lack of substantial evidence' and 'inconsistency of study results' regarding the drug's efficacy. This news led to Aldeyra Therapeutics' stock falling by $2.99 per share, a 70.69% decrease, on March 17, 2026. The lawsuit alleges securities fraud and other unlawful business practices by Aldeyra Therapeutics and its officers/directors.

Key Actions

100 Pomerantz LLP filed class action lawsuit Aldeyra Therapeutics

95 United States — Food and Drug Administration issued Complete Response Letter Aldeyra Therapeutics

90 Aldeyra Therapeutics stock price fell

Entities Involved

stock

Aldeyra Therapeutics

Aldeyra Therapeutics is facing a class action lawsuit due to alleged securities fraud after its drug candidate, Reproxalap, received a Complete Response Letter from the United States — Food and Drug Administration, causing a significant drop in its stock price.

Importance 100 Sentiment -90

priv

Pomerantz LLP

Pomerantz LLP is the law firm that filed the class action lawsuit against Aldeyra Therapeutics, representing investors who suffered losses.

Importance 80 Sentiment 20

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration issued a Complete Response Letter for Aldeyra Therapeutics' drug candidate, Reproxalap, citing a lack of substantial evidence for its efficacy, which triggered the stock price drop and subsequent lawsuit.

Importance 70 Sentiment 0

oth

Reproxalap

Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.

Importance 60 Sentiment -80

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard